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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S477C8, C12, C15, C16, C18 linear alkyl amines and a benzyl amine, were
tested for the inhibitory activity against ChC. The inhibitor potency
showed to be directly correlated to the length of the alkyl chain. The C16
alkyl amide derivative HYADD4 was identiﬁed as lead compound (Ki¼
6.21.6 mM), on the basis of the best compromise between potency and
solubility.
With the aim of assessing the speciﬁcity of the effect, HYADD4 was
then screened vs 10 different human MMP catalytic subunits, showing
higher selectivity for MMP8 and MMP13. The Ki against human MMP13
was found to be in the micromolar range (61.7  7.0 mM).
Finally, since MMP13, unlike MMP8, is involved in OA progression, an ex
vivo study was performed by incubating HYADD4 in SF from patients
with inﬂammatory arthritis: the Ki value obtained (106.1  9.2 mM) was
comparable to that observed in vitro, thus validating the inhibitory
activity against MMP13.
Conclusions: These data suggest that the extremely hydrophobic side
chain of HYADD4, whose water solubility is boosted by the HA back-
bone, is pivotal in the mechanism of MMP competitive inhibition.
The polymer structure suggests that the alkyl side chain could easily
and selectively dock the hydrophobic S1’ pocket in the MMP catalytic
domain.
The hexadecyl derivative shows the best performance against MMP13
and MMP8, as conﬁrmed also in an ex-vivo experiment in SF vs human
MMP13. Furthermore, the intra-articular administration of the alkyl-
modiﬁed HA as a treatment for OA, thanks to its site-selectivity and
solubility, can overcome the common issues of the small molecule MMP
inhibitors, such as systemic distribution and toxicity.
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EVALUATION OF A POLYACRYLAMIDE HYDROGEL IN THE
TREATMENT OF INDUCED OSTEOARTHRITIS IN A GOAT MODEL: A
RANDOMIZED CONTROLLED PILOT STUDY
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Purpose: Polyacrylamide hydrogel (PAAG) is an inert, non-degradable,
non-immunogenic polymer gel with high viscoelasticity consisting of
97.5% sterile water and 2.5% cross-linked polyacrylamide. Its bio-
compatibility in soft tissues has been demonstrated. PAAG has recently
been tested for the treatment of osteoarthritis (OA) in horses with
highly encouraging results; however no standardized experimental
studies have been done to explore its efﬁcacy. The purpose of this study
was to evaluate PAAG in the treatment of induced OA in a goat model.
Methods: A randomized controlled study was conducted involving
goats with induced OA on the left stiﬂe (knee) joint. OA was surgically
induced by the transection of the medial collateral ligament, the
bisection of the medial meniscus at its midpoint and partial-thickness
incisions of the cartilage of the medial tibial plateau. Goats were
allowed free exercise, and 3 months after surgery they were randomly
divided into 2 groups: group 1 (n¼ 4): PAAG and group 2 (n¼ 2): saline
solution (control). Treatments were injected intraarticularly. MRI of the
left knee had been performed prior to surgery, at the time of injection (3
months) and 4, 5 and 7 months post-surgery. T1, T2/PD and Stir
weighted MRI images were used to assess OA. All goats were clinically
evaluated on ground and on treadmill and videotaped for evaluation by
3 blinded observers. Haematology, biochemistry and acute phase pro-
teins were also assessed. The goats were euthanized 7 months after
surgery, and gross pathology and histopathology, including immuno-
histochemistry for nerve endings (n ¼ 3 joints), were performed on
both femorotibial joints. The hardness of the joint capsule was meas-
ured in both groups using Instron  5564 testing system (HIS Global-
Spec, MA, USA).
Results: At the end of the study, 75 % of the goats treated with PAAG
were clinically sound, and 25 % of them had not improved, whereas the
2 control goats were still lame. In both groups, the values of haema-
tology, biochemistry, or acute phase proteins werewithin normal range.
MRI showed that in group one, 3 out of 4 goats had a decrease followed
by a stabilization of OA lesions, while 1 goat had a mild progression of
the OA lesions. In group 2, both goats had a mild or marked increase ofOA lesions. Gross pathology inspection in group 1 demonstrated that all
the operated knees showed typical signs of OA. The inner synovial lining
was thickened, and the cartilage surface was uneven in all cases. The gel
was seen in various amounts adhering to the inner side of the joint
capsule in all the goats of group 1. Gross inspection of both goats in
group 2 also showed cartilage lesions and synovial thickening, but the
histopathological investigations revealed this to be more prominent in
group 1 than in group 2. It comprised angiogenesis, collagen and
synovial cell increase, and in the injected goats, also the gel. The nerve
endings were normal looking and in normal numbers. The investigation
of the joint capsule hardness showed that in the treated knee of the
goats of group 1, the medial side (injected with PAAG) was always less
hard than the lateral side.
Conclusions: This study demonstrated the efﬁcacy of a novel treat-
ment of OA, with 75 % of the goats treated with PAAG being clinically
sound. Treatment with PAAG did not have any inﬂuence on haema-
tology, biochemistry, or acute phase proteins. It induced a moderate
synovial hyperplasia of the inner side of the capsule with trapped
(integrated) gel, increased angiogenesis and collagen production. Pre-
liminary pathology and joint capsule hardness data suggest that PAAG
might act mainly on the joint soft tissue and especially the synovial
membrane. PAAG might have 2 effects on OA joints: 1- Joint capsule
was less hard on the treated (medial) than on the non-treated (lateral)
side and had a lower hardness when compared to group 2. OA joints
typically show joint stiffness - a major source of pain in OA. By
decreasing the joint capsule hardness, and thus joint stiffness, PAAG
might relieve the pain in the OA joint (“disease-modifying” effect). 2-
MRI and pathology investigations have revealed a stabilization of OA
lesions in the goats of group 1, which might be explained by the
mechanical effect through the high viscosupplementation provided by
PAAG that was still present in the joint cavity (“disease-stabilizing”
effect). No adverse reaction was seen following intraarticular injection
of PAAG. More investigations are needed to fully understand the
mechanism of action of PAAG in improving clinical signs and in sta-
bilizing OA. This pilot study may be used as a basis for further studies
using larger animal numbers.
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EVALUATION OF NANOSTRUCTURED VECTORS FOR THE TREATMENT
OF OSTEOARTICULAR PATHOLOGIES
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Purpose: One of the major problems in treatment of osteoarticular
diseases is to reach cells inside the matrix to provide drug. Indeed,
cartilage is an avascular tissue with a few cells feed by diffusion through
a dense protein network (collagens, glycosaminoglycans). In this work
we have designed polymeric nanoparticles (NPs) of poly (D, L-lactic/glycolic acid)(PLGA) synthesized by a double emulsion method, which
are biocompatible, biodegradable and can encapsulate water-soluble
agents. Our NPs are labelled with BSA coupled to a ﬂuorescent dye
(Cyanine-3) to follow them by epiﬂuorescent microscopy. As articular
Initial + 16ml XOD +32 mL XOD
HA 0.8% MW 787 000 Da 621 450 Da 498 900 Da
Mannitol 3.5% + HA 0.8% MW 768 900 Da 717 750 Da 677 150 Da
1st 5th Change
SF volume (ml) 14.2 7.3 6.9 P < 0.05
HA (mg/ml) 1.50 1.72 0.22 P < 0.05
C4S (nmol/ml) 17.5 16.0 1.5 P < 0.05
C6s (nmol/ml) 59.7 50.2 9.5 P < 0.05
KS (mg/ml) 6.62 6.23 0.39 NS
IL-6 (pg/ml) 3733 457 3276 P < 0.05
Viscosity (mPa∙S) 49.6 72.5 22.9 P < 0.05
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component of synovial ﬂuid), the nanoparticles are recovered with HA
in order to enhance targeting of cells. Here, we have studied the
internalization kinetics of “empty” nanoparticles, and we have eval-
uated their neutrality on chondrocytes matrix synthesis, mesenchymal
stem cell (MSC) differentiation and inﬂammatory response. Innocuity
has been also evaluated in healthy animals, after direct intraarticular
injection of labelled nanoparticles (inﬂammatory response, Extrac-
ellular matrix integrity).
Methods: Articular cells (chondrocytes, synoviocytes) and MSC are
isolated from human donors, and cultured as primary culture. First, cells
are exposed with 100 mg/mL of NPs from 2 to 12 hours. At the end of the
kinetic immunoﬂuorescence pictures with DAPI (nuclear staining) are
realized to assess of the internalization of NPs, expression of inﬂam-
matory markers (IL1ß, TNFa and Cox2) are monitored by RT-qPCR
analysis, and conﬁrmed by PGE2 and nitrites measurement in
supernatant.
In other hand we evaluate, with pellets culture system, the effect of NPs
exposition on extracellular matrix synthesis by chondrocytes, with RT-
qPCR analysis of speciﬁc markers (Col2, Aggrecan and COMP), and by
histological study of pellets (Alcian blue staining of proteoglycans, Sirius
Red staining of collagen). Finally by growing MSC into 3 different dif-
ferentiation media, we investigate if NPs pre-treatment can interfere
with differentiation ability of MSC onto chondrogenic, adipogenic or
osteogenic pathway. RT-qPCR assays for differentiation markers
according to culture conditions and speciﬁc staining of lipid vesicles or
calcium deposits, allow us to conﬁrm the differentiation of cells.
Intraarticular injections were realized in healthy rat’s Knees. Structure
of joint (synovium, cartilage, subchondral bone) was assessed by his-
tological studies, performed at 7 and 10 days after injection (single and
repeated).
Results: For the different cell types, NPs are found into cytoplasm after
6 hours of exposition.
Internalization of these NPs leads to an increase of inﬂammatory
markers between 4 and 8 hours, basal level of expression being reached
after 12 hours. Even if there is a weak increase of PGE2 and nitrites
synthesis, that stay signiﬁcantly lower than with LPS stimulation, our
positive control of inﬂammation. NPs exposure, prior or after IL-1ß
stimulation, does not aggravate the inﬂammatory response of these
cells. When chondrocytes are exposed to NPs for 24 hours and then
cultured in pellets for 28 days, there is no difference in matrix synthesis
for the expression of mRNA and matrix deposition, as conﬁrmed with
histological exams. RT-qPCR and staining assays have also shown that
despite a pretreatment with NPs, MSCs can be conducted onto adipo-
genic, osteogenic or chondrogenic differentiation pathways. Histo-
logical analyses of extracellular matrix integrity and inﬂammatory
status do not demonstrate any differences for cartilage and subchondral
bone structures but reveal a weak hyperplasia of synovial membrane,
increasing with NPs concentration and the number of injection.
Conclusions: These NPs are rapidly internalized by human articular
cells, with only moderated and transient pro-inﬂammatory effects. In
addition there is no side effects on (1) ECM synthesis by chondrocytes
or MSC and (2) differentiation process due to the presence of NPs.
Labelled NPs with Cya3, once injected in joint of healthy rat, do not lead
to an inﬂammatory reaction and/or modiﬁcation of extracellular matrix
integrity. NPs are mainly found in synovium and repeated injections do
not generate severe adverse reaction. This drug delivery system can be
used to deliver an active molecule into the knee joint, thanks to the
absence of side effects.
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Purpose: Osteoarthritis(OA) is a degenerative joint disease associated
with harmful action of reactive oxygen species (ROS). ROS are involved
in the degradation of both aggrecan and high-molecular-weight hya-
luronan (HMW-HA). The later plays a key-role in the joint lubrication
and the visco-elastic and shock absorbing properties of the synovial
ﬂuid (SF). Viscosupplementation consists to inject intraarticularly
exogenous HMW-HA to restore the SF rheological properties, that aredramatically decreased in OA. However the injected HA is also rapidly
degradated by ROS, decreasing its effectiveness and duration of action.
The study objective was to evaluate the ability of Mannitol, a powerful
oxygen free radical scavenger, to reduce HMW-HA ROS mediated deg-
radation using a model of oxydative stress induced by xanthine (X) þ
xanthine oxidase (XOD). XOD is a ﬂavoprotein that catalyzes oxidation
of hypoxanthine to xanthine and then to uric acid generating high levels
of superoxide anion.
Methods: Hyaluronan (MW# 0.8mDa) was submitted to an oxidative
stress generated by the addition of X þ XOD. Then solution of the same
HA þ 35g/L of Mannitol in PBS buffer was studied. Different enzyme
concentrations were used and the HA properties were studied after 24
hours of contact at ambient temperature. Changes of the viscosity of the
solution were assessed by rheometry with a rheometer at 25 C using a
cone and plate geometry; steady-state viscosity was determined in Pa.s,
as a function of the shear rate. HA MW was also determined by steric
exclusion chromatography before and after oxydative stress.
Results: The presence of X/XOD degraded HA : 1) HA viscosity
decreased as a function of XOD concentration, 2) HA MW decreased
dramatically by 36.6%.On the opposite the presence of Mannitol stabi-
lized HA : 1) HA viscosity remained stable, 2) HA MW decreased only
slightly (-11.9%).
Conclusions: High concentrations (35g/L) of mannitol protect HA from
ROS-mediated degradation. These in vitro data suggest that mannitol
may increase the intra-articular residence time of HA and consequently
may improve efﬁcacy and/or effectiveness duration of viscosupple-
mentation.
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CHANGES OF THE BIOMARKERS IN SYNOVIAL FLUID AND CLINICAL
EFFICACY OF INTRA-ARTICULAR INJECTION HYALURONIC ACID FOR
PATIENTS WITH KNEE OSTEOARTHRITIS
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Purpose: Intra-articular injection hyaluronic acid (HA) for the treat-
ment of patients with knee osteoarthritis (OA) has been commonly used
in Japan. However, American Academy of Orthopaedic Sugerons (AAOS)
announced intra-articular hyaluronic acid is no longer recommended in
the 2013 guideline. Efﬁcacy of the intra-articular HA still remain con-
troversial. We have performed ﬁve weekly HA injections according to
the Japanese insurance policy. Many biomarkers are reported: some
biomarkers reﬂects cartilage metabolism and the others reﬂects
inﬂammation reaction. We examined HA, chondroitin 4-sulfate (C4S),
chondroitin 6-sulfate (C6S), keratan sulfate (KS) for cartilage metabolic
biomarker and interleuikin-6 (IL-6) for inﬂammation biomarker. Il-6 is
well known as inﬂammation cytokine in the patients with rheumatoid
arthritis, but the change of Il-6 levels treated by the intra-articular HA in
the patients with OA has not been reported. The purpose of this study
was to investigate the change of the viscosity and biomarkers of
synovial ﬂuid and clinical symptoms before and after ﬁve weekly HA
injections.
Methods: Fifty seven patients (61 knees) with symptomatic knee OA
were enrolled between January 2010 and July 2013. We conducted 5
